Zhihao Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhihao Hu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Changhong Shi
Division of Cancer Biology, Laboratory Animal Center, Air Force Medical University, Xi’an, China
23 shared publications - Chao Xu
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
23 shared publications - Donghui Han
Department of Urology Xijing Hospital Fourth Military Medical University Xi'an China
23 shared publications - Fa Yang
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
23 shared publications - Hongji Li
Department of Urology, Xijing Hospital, Air Force Medical University, Xi’an, China
23 shared publications - Hongtao Song
Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
23 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 5: Human primers for qRT-PCR analysis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 6: The clinical information of scRNA-seq data and the numbers of cells in each sample
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 3: Antibodies for Flow Cytometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 4: Antibodies for Western Blot and immunofluorescence staining
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 1: The clinical information of patients and TMA
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S5 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Figure S1. ScRNA-seq and RNA-seq revealed the ECM-CAF and Lym-CAF. Supplementary Figure S2. Lym-CAF promotes anti-tumor immunity via NF-κB p65. Supplementary Figure S3. ECM-CAF is associated with ECM genes and YAP1. Supplementary Figure S4. YAP1 silencing promotes the secretion of CXCL9/10/11. Supplementary Figure S5. CD248 is a specific biomarker of ECM-CAF.
- Open Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size
- 18 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer
Supplementary Table 2: Genotyping Primers and expected band size